RYZ101 + Standard Treatments for Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug, RYZ101, combined with standard cancer treatments in patients with a specific type of untreated lung cancer. The new drug aims to target certain receptors on cancer cells, while the other drugs work to kill the cancer cells and help the immune system fight them.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on antibiotics or have recently had a live vaccine, you may need to wait before starting the trial.
What data supports the effectiveness of the drug combination RYZ101, Atezolizumab, Carboplatin, and Etoposide for treating small cell lung cancer?
Is the combination of RYZ101 and standard treatments for small cell lung cancer safe for humans?
The combination of atezolizumab (Tecentriq) with carboplatin and etoposide has been generally well tolerated in patients with extensive-stage small cell lung cancer, with no new safety concerns beyond those known for the individual drugs. Common side effects include blood-related issues, skin rash, and low thyroid function, but it did not negatively affect patients' quality of life.13567
What makes the drug RYZ101 combined with standard treatments unique for small cell lung cancer?
The drug RYZ101 combined with standard treatments for small cell lung cancer is unique because it includes atezolizumab, an immune checkpoint inhibitor that has been shown to improve survival when added to the traditional chemotherapy regimen of carboplatin and etoposide. This combination represents a newer approach that enhances the body's immune response against cancer cells, offering a significant advancement over previous treatments that relied solely on chemotherapy.358910
Eligibility Criteria
This trial is for adults with untreated ES-SCLC that expresses somatostatin receptors. Participants must have adequate organ function, no severe allergies to certain drugs or cell products, and not be pregnant or breastfeeding. They should not have had major surgery recently, active infections like TB or hepatitis, significant heart disease, other cancers in the last 3 years (with some exceptions), or a history of severe allergic reactions.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RYZ101 in combination with standard of care therapy (carboplatin + etoposide + atezolizumab)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atezolizumab (Monoclonal Antibodies)
- Carboplatin (Other)
- Etoposide (Other)
- RYZ101 (Other)
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma